Skip to main content
. 2011 Mar 25;52(3):1684–1692. doi: 10.1167/iovs.10-6397

Figure 4.

Figure 4.

ILK siRNA knocks down ILK expression. (A) Levels of ILK expression in differentiated N27TM-2 cells treated for 48 hours with ILK siRNA. The blot is representative of the same experiment in three different cell strains. (B) Cell spreading was impaired in HTM cells treated with 50 nM of ILK siRNA compared to control siRNA or lipofectamine 2000 unless the Hep II domain was present. Cells were plated on the CBD for 3 hours in the absence or presence of the Hep II domain and labeled with phalloidin to visualize F-actin. Bar, 20 μm. (C) Treatments of 25 and 50 nM ILK siRNA significantly decreased cell spreading. Statistically significant (*P < 0.05, **P < 0.0001). Data are the mean ratio of cell area compared to Lipofectamine only control (set to 100%) ± SEM for non-Hep II domain–treated cells and compared to lipofectamine + Hep II for cells treated with the Hep II domain. Cell spreading was quantified by measuring the area of the cells in four to six fields of view from a triplicate experiment (n = 123).